Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.

ABSTRACT:

Background

Optimizing multiple sclerosis treatment warrants understanding of changes in physical, mental, and social health.

Objective

To assess the impact of natalizumab on Quality of Life in Neurological Disorders (Neuro-QoL) scores.

Methods

Annualized change in T-scores and likelihood of ≥5-point improvement over baseline were calculated for each Neuro-QoL domain after natalizumab initiation. Comparisons with ocrelizumab-treated patients were conducted after propensity score weighting and adjustment for relevant co-medications, year, and drug-year interaction.

Results

Among 164 natalizumab patients analyzed, 8 of 12 Neuro-QoL domains improved significantly, with greater improvement in patients with abnormal baseline Neuro-QoL. In the subgroup comparison of n

SUBMITTER: Hersh CM 

PROVIDER: S-EPMC8053767 | biostudies-literature | 2021 Apr-Jun

REPOSITORIES: biostudies-literature